Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 7639


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Ophthalmological

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7639

License Grant
The Israel Licensor signed an Agreement regarding the provision of a License for its CF101 drug with a South Korean pharmaceutical Licensee. The Licensor granted a License to use, develop and market its CF101 drug for treating only rheumatoid arthritis only in the Republic of Korea.
License Property
CF101 drug for treating only rheumatoid arthritis only.
Field of Use
The Licensee researches and develops over the counter and prescription drugs in South Korea.

IPSCIO Record ID: 7215

License Grant
Licensor hereby grants a Korean  pharmaceutical company an exclusive royalty-bearing license, with the right to sublicense directly or through multiple tiers under the Licensor Technology, to research, Develop, Finish, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed, import, have imported, and otherwise Commercialize the Products in the Field in the Territory.  For clarity, the foregoing licenses exclude the right to Manufacture or have Manufactured the Product, except for the right to Finish the Product.
License Property
The Licensee has made or will make certain specified milestone payments to the Licensor upon the signing of the Agreement, a specified period of time following approval of ZertaneTM for sale in South Korea, a specified period of time following approval of a combination drug for sale in South Korea and specified periods of time following the end of the first calendar quarter where cumulative net sales of products including ZertaneTM (including combination drugs) in South Korea exceed specified thresholds.
Field of Use
The Agreement provides the Licensee with exclusive rights to market ZertaneTM in South Korea for the treatment of premature ejaculation and for a combination drug, utilizing ZertaneTM and another erectile dysfunction drug (PDE5 inhibitors and others), to simultaneously treat premature ejaculation and erectile dysfunction.

IPSCIO Record ID: 28715

License Grant
Pursuant to an acquisition agreement, the Party entered into a License Agreement, in which Can-Fite granted the Licensee a sole and exclusive worldwide License for the use of CF101.
License Property
CF101 (known generically as IB-MECA), is being developed to treat three ophthalmic indications dry eye syndrome; glaucoma and uveitis. We are currently (i) conducting a Phase III trial with respect to the development of CF101 for dry eye syndrome, under an Investigational New Drug, or IND, application with the United States Food and Drug Administration, or FDA; (ii) conducting a Phase II trial with respect to the development of CF101 for the treatment of glaucoma; and (iii) preparing for Phase II study of the development of CF101 for uveitis.
CF101 is a highly-selective, orally bioavailable small molecule synthetic drug, which targets the A3 adenosine receptor (A3AR). We believe that CF101 has a favorable safety profile and a potent anti-inflammatory activity, mediated via its capability to inhibit the production of inflammatory cytokines, such as TNF-a, MMPs, IL-1, and IL-6. This is mediated by activation of the A3AR, which is highly expressed in inflammatory tissues in contrast to normal tissues where expression levels of the receptor are very low. We believe that the anti-inflammatory and neuroprotective effects of CF101 make it an attractive candidate for use in the treatment of a variety of ophthalmic diseases.
Field of Use
The field of ophthalmic diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.